Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

Mylan has been in the news for hiking prices on its EpiPen. The stock is flat since we recommended it in March, but we now ...

Detailed price information for Elanco Animal Health Inc (ELAN-N) from The Globe and Mail including charting and trades.

Chardan Capital dropped their target price on Rocket Pharmaceuticals from $62.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Leerink Partners dropped ...

NEW YORK--(BUSINESS WIRE)--Nussbaum Law Group, P.C. and Roberts Law Firm US, PC: A proposed settlement (“Settlement”) has been reached in a class action lawsuit alleging that Mylan N.V., Mylan ...

The stock is down 17.3% since reporting ... Is now the time to buy ANI Pharmaceuticals? Access our full analysis of the earnings results here, it’s free. Formed in 2020 through the merger of Mylan and ...

Viatris Inc., formed in 2020 through the merger of Mylan and Upjohn (a former ... as a significant player in the pharmaceutical industry. The company’s stock has shown mixed performance, with ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed ...

Keeping that in mind, here is one healthcare stock poised to generate sustainable market-beating returns and two we’re swiping left on. Formed in 2020 through the merger of Mylan and Upjohn ...

The stock finally dropped into free fall today, plunging more than 15 percent to mark one of the company’s worst trading days since it went public in 2010. The tumble erased the last vestiges of ...

Aug 20 (Reuters) - Teva Pharmaceutical Industries (NYSE:TEVA) Ltd TEVA.TA said on Tuesday its generic version of Mylan's MYL.O ...